Coloplast CEO on expectations: "There are many swing factors"

When Coloplast's CFO Anders Lonning-Skovgaard looks from one Covid-stricken year to the next, he assumes that health authorities worldwide have improved their ability to handle the coronavirus pandemic and that Coloplast and its growth target will be less affected than previously, if infections and hospitalizations go back on the rise.
EVP Coloplast EVP and CFO Anders Lonning-Skovgaard. | Photo: Coloplast / PR
EVP Coloplast EVP and CFO Anders Lonning-Skovgaard. | Photo: Coloplast / PR
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN

After a year of troubled waters because of the Covid-19 pandemic, Coloplast has a feeling it's headed towards a more positive and stable time. The Danish medtech firm has positive expectations for the coming fiscal year, where it aims to have organic growth at 7-8 percent and earnings at between 31-32 percent.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading